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Introduction
Hypertension or high blood pressure (BP), a major risk factor for the development of cardiovascular disease (CVD), is an especially significant threat to the health of women. The Framingham Heart Study (FHS) estimated that the lifetime risk of hypertension (i.e. probability of developing hypertension during the remaining years of life) for middle-aged (55 years old) and elderly (65 years old) individuals to be 90% in women and 80% in men [1] . This high probability of middle-aged and elderly individuals, particularly women, developing hypertension over their remaining lifespan indicated that hypertension is becoming an increasingly important medical and public health issue given our ageing population.
Hypertension has also been shown to be an important modifiable risk factor for cognitive impairment [2] . Although it is not exactly known when hypertension may begin to exert its influence on the brain and cognition, studies have reported elevated BP during middle age to be associated with increased neuropathology [3, 4] as well as cognitive impairment and dementia [5, 6] at later ages. However, there is now evidence showing that the adverse health effects (e.g. CVD and mortality) associated with elevated BP begin at much lower levels (e.g. BP = 115/75 mmHg) than initially believed [7, 8] . A new classification termed 'Prehypertension' (SBP = 120-139 mmHg or DBP = 80-89 mmHg) was therefore introduced in the most recent Seventh Report of the Joint National Committee ( JNC-7) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure to identify individuals who may benefit from early intervention, thereby reducing the rate of progression of BP to hypertensive levels [9] . As CVD is a significant risk factor for cognitive impairment and dementia, it would be reasonable to assume that this increase in cardiovascular risks from prehypertension levels would correspond to an increased risk in cognitive impairment and dementia. There is only one study that has examined the associations between prehypertensive BP levels on cognitive functioning. In the Maine-Syracuse Longitudinal Study of Hypertension (MLSH), Elias et al. [10] reported that moving from every unit increase in JNC-7 BP categories at baseline was associated with a significant decline in visualisation/fluid abilities in both younger (age range = 18-46 years) and older (age range = 47-83 years) adults. While this finding suggests the adverse effects of hypertension on cognition could begin at a much lower level, there is a need for further studies to be conducted to further confirm this association.
Our study, therefore, sought to contribute to the existing literature by examining the associations between midlife BP levels ( JNC-7 categories) and subsequent cognition in middle-aged and older women. Given that prehypertension is common in white postmenopausal women [11] , and older women are particularly at risk of developing dementia compared with men [12] , this is an especially important population group.
Methods

Study population
The subjects were participants of the prospective longitudinal Women's Healthy Ageing Project (WHAP) which commenced in 1991 as the Melbourne Women's Midlife Health Project [13] . The initial study design and methods have been described in detail elsewhere [14] . Briefly, households were selected via random telephone dialing, and 2001 eligible white women (Australian-born, aged between 45 and 55 years and currently residing in Melbourne) participated in the initial cross-sectional survey in 1991 (see Supplementary data, Appendix 1 available in Age and Ageing online). In 1992, 438 women who had menstruated in the 3 prior months and were not currently using oral contraceptives or hormone therapy were invited and agreed to participate in the longitudinal study. These 438 women were subsequently interviewed annually over 8 years (1992-99) and again in 2002. BP was measured in all testing sessions, while in 2002, these participants were also administered a comprehensive neuropsychological battery [15, 16] . Present analyses were restricted to a subsample of 247 women who had BP measurements taken in both 1992 and 2002, as well as complete cognitive data. For details regarding the exclusion criteria and comparisons between participants remaining in this study and those lost to follow-up, see Supplementary data, Appendix 1 available in Age and Ageing online. All study procedures were approved by the Human Research Ethics Committee at the University of Melbourne.
Cognitive assessments
Cognitive tests were administered by trained psychologists at follow-up (2002). Detailed testing procedures, descriptions of tests as well as normative data on this cohort have been published previously [15] [16] [17] [18] . The primary purpose of this study was to ascertain the relationship of BP and age-and dementiasensitive cognition; therefore, we limited the reporting of data to cognitive measures of executive functioning, speed of processing and verbal episodic memory. Executive function was evaluated using the Trail-Making Test, Part B (TMT-B) [19] , and psychomotor speed was assessed with the Symbol Digits Modalities Test-oral version (SDMT) [20] . Verbal episodic memory was evaluated using the Australian-modified California Verbal Learning Test (CVLT) [16] and a 10-item supraspan word-list task [21] . Z-scores were computed for immediate memory and delayed memory separately for CVLT and the 10-item supraspan word list. A composite z-score for immediate and delayed memory was then computed across these two word-list learning tests.
BP measurements
At each examination, BP was measured using an electronic BP monitor with participants in a seated position. The cuff was placed on the rested upper arm, with the cuff 's lower edge about an inch above the elbow. The same procedure was repeated twice, 5 min apart, and the measures were averaged to obtain a per-visit mean BP. Baseline (1992) and follow-up (2002) BP levels, in millimetres of mercury (mmHg), were categorised according to the JNC-7 guidelines [9] : normotension (SBP < 120 and DBP < 80); prehypertension (SBP = 120-139 or DBP = 80-89); and combined Stage 1 and Stage 2 hypertension (SBP ≥ 140 or DBP ≥ 90). If the SBP or DBP readings for a participant were in different categories, the higher of the two categories was used.
Statistical analysis
Differences in characteristics of women in the BP groups were analysed using independent-samples analyses of variance or χ 2 tests as appropriate. Separate between-group analyses of covariance were then performed to investigate the effects of BP on cognition, with the independent variables being the JNC 7 categories (Normotensive, Prehypertensive and Hypertensive) in 1992 and 2002 and the dependent variables the individual cognitive scores in 2002. Regression models on JNC-7 groups at age 50 years and late-life cognition (age 60 years) included co-variates obtained at age 50 years, while regression models on JNC-7 groups and cognition at age 60 years included co-variates obtained at follow-up. Only the use of hormone therapy is included at the follow-up regression analyses as women at baseline were premenopausal and not on any hormone therapy. Co-variates include age, years of education, smoking status, alcohol consumption over the last week, antihypertensive treatment, body mass index, use of hormone therapy, total cholesterol, history of vascular conditions and negative mood score [22] . Details on the co-variates can be found in Supplementary data, Appendix 2 available in Age and Ageing online. Bonferroni corrections were performed to examine group differences while controlling for multiple comparisons. Due to the mathematical adjustments employed by SPSS, Bonferroni corrections were set at an alpha level of 0.05. All data were analysed using IBM SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA). Table 1 shows the baseline (1992) and follow-up (2002) characteristics of 247 participants. Compared with baseline, participants at follow-up had more vascular risk factors, such as elevated BP, and a higher percentage of women reported being diagnosed with vascular conditions and are on antihypertensive treatment. The characteristics of participants according to the JNC-7 grouping are summarised in Supplementary data, Appendix 3 available in Age and Ageing online. Significant JNC-7 group differences, at baseline and follow-up, were noted for age, education, body mass index, history of vascular conditions and the use of antihypertensive medications (Supplementary data, Appendix 3 available in Age and Ageing online).
Results
There was a significant effect of BP group at baseline (mean age = 50 years) on processing speed (P = 0.046) and immediate (P = 0.003) and delayed (P = 0.049) episodic memory 10 years later, even after controlling for all co-variates (Table 2) . Post hoc analyses showed that normotensive women had significantly better immediate memory than those who had prehypertensive (P = 0.008) and hypertensive (P = 0.019) BP levels ( Table 2) . Normotensive women also recalled significantly more words than prehypertensive women following a delay (P = 0.043). At follow-up (mean age = 60 years), there is a significant effect of BP group on concurrent immediate episodic memory (P = 0.046), and not with any other cognitive functions, although post hoc analyses did not show any significant pair-wise comparisons.
In additional analyses, we examined the effects of vascular conditions and antihypertensive treatments on BP-cognition relationship. History of vascular conditions at baseline and follow-up was not associated with cognitive performance (all P values >0.05), and excluding women with a history of vascular conditions (n = 121) did not change the results (data not shown). The BP group by vascular conditions interaction at baseline and follow-up was also not significant (all P values >0.05), suggesting that the effect of BP group on cognition did not differ by the presence of vascular conditions. We also examined the effect of antihypertensive treatment on the BPcognition relationship separately for those with (n = 62) and without (n = 185) a history of antihypertensive treatment. Compared with the 62 excluded hypertensive-treated women, participants included in this analysis had lower SBP, DBP and BMI, and furthermore, fewer women were diagnosed with vascular diseases. In the antihypertensive-treated group, there was no significant effect of BP group, at both baseline and follow-up, on all cognitive performance (all P values >0.05). In contrast, multivariate analyses performed on the nontreated group showed a significant effect of baseline JNC-7 group on processing speed (P = 0.027) and episodic memory (immediate: P = 0.005; delayed: P = 0.034) ( Table 3) . Post hoc analyses, following Bonferroni corrections, showed that normotensive participants had faster processing speed and better immediate episodic memory than their prehypertensive and hypertensive peers. At follow-up, BP groups at age 60 years were associated with concurrent immediate (P = 0.041) and delayed (P = 0.042) episodic memory, with post hoc analyses showing women with prehypertension performing significantly better than their hypertensive peers.
Discussion
In this population-based, longitudinal study of high-functioning middle-aged and older women, we examined the prospective and cross-sectional associations between BP levels and late-life cognition. In particular, optimal BP level (BP < 120/80 mmHg) measured at age 50 years (in the total sample as well as in a subsample of untreated women) was related to better performance on processing speed and episodic memory 10 years later, even after controlling for various demographic and health variables. At late life, untreated hypertension measured at the time of cognitive testing (mean age = 60 years), compared with prehypertension levels, was significantly associated with poorer immediate and delayed memory. Our finding that midlife hypertension is inversely associated with episodic memory and processing speed a decade later is consistent with previous findings [23 -25] . In particular, our study showed that the adverse cognitive effects, particularly on immediate memory, could possibly begin from as low as the prehypertensive levels (SBP = 120-139 mmHg or DBP = 80-89 mmHg). As midlife hypertension has been previously demonstrated to be associated with AD neuropathology in the hippocampus, which generally results in memory impairments [4] , our findings suggest the possibility that prehypertensive midlife BP levels may already have an effect on neuropathology resulting in poorer episodic memory. This, in conjunction with age-related decrements in cognition, suggests that individuals with midlife prehypertension could subsequently experience a steeper cognitive decline later in life, which could result in dementia, compared with their normotensive peers.
There is a growing recognition of the adverse health effects of BP at much lower levels as previously thought; therefore, the term 'prehypertension' by JNC-7 was aimed to identify and prevent people at high risk of developing hypertension and CVD. Our current findings provide support for this classification by demonstrating that hypertension-related cognitive impairments could begin at prehypertensive levels in midlife. In this regard, prehypertension as a BP category could allow identification of those not only at risk of hypertension and subsequent CVDs, but also development of future reduced cognition. Although individuals with prehypertension are currently not candidates for pharmacological interventions [9] , our findings suggest that individuals with prehypertension should be encouraged to adopt lifestyle modifications in an effort to reduce their risk of developing hypertension and of cognitive impairment. The association between hypertension and cognition appears to be influenced by antihypertensive treatment. In our study, elevated BP is associated with poorer episodic memory, but only in untreated women. This finding that antihypertensive treatments may mediate the effects of hypertension to cognitive impairment is consistent with previous studies that reported treated hypertensive individuals to perform better than their untreated counterparts but still less well than those who are normotensive [26] . In this regard, the use of antihypertensive treatment may underestimate the associations between hypertension and cognition. It should be noted that the interpretation of the effect of antihypertensive medication on cognition is limited by its observational design. Clinical trials are needed to better understand the effects of antihypertensive treatments on cognition.
While hypertension has been shown to be a significant risk factor for cognitive impairments, hypotension has also been shown to be associated with subsequent cognitive impairments and dementia in older adults [27] . The examination of the associations between hypotension and cognitive functioning in the current WHAP cohort is unfortunately limited due to the small number of hypotensive participants (eight participants at baseline and one participant at follow-up) in the current WHAP cohort which limits the statistical power for analyses. As the hypotension-cognition relationship is more commonly reported in studies involving older adults (65 years and older) [27] , further research in this cohort of women who are currently being followed in the next decade would be a better opportunity to investigate the hypotension-cognition relationship.
To the authors' knowledge, this study is one of the few women-specific prospective cohort studies to have examined and demonstrated that midlife prehypertensive BP level is associated with subsequent reduced cognition at late life. Potential limitations include a study population of relatively high-functioning and young middle-aged women that might limit the power to detect small cognitive changes in these women. As the study consists of female participants, findings are therefore only generalisable to women. Cognitive assessment was assessed at a single time point; therefore, it would be difficult to ascertain whether the worse cognition is a result or by-product of elevated BP levels. The observed associations were of borderline statistical significance, and hence future epidemiological research, particularly those with a larger sample size and a diverse population, is needed to determine the clinical significance of the observed BP-cognition relationship. Lastly, current information on medical history and medication use is based on self-reports, and therefore, this information may subject to participant bias.
In summary, findings from this study demonstrated that elevated BP at age 50 years, even at prehypertensive levels and independent of antihypertensive treatment, is a significant predictor of reduced cognitive functioning a decade later. In particular, our findings highlight the potential relevance and importance of the prehypertension category by the most recent JNC-7 report for early identification of adults not only at risk of developing hypertension, but also cognitive decline. In this regard, it is important that interventions to prevent an increase in BP levels are implemented as early as possible in life.
Key points
• There is a growing recognition of the adverse health effects of BP at much lower levels as previously (e.g. BP = 115/75 mmHg), yet few studies have examined the effects of prehypertension on cognitive functioning.
• In this study, elevated BP at age 50 years, even at prehypertensive levels and independent of antihypertensive treatment, is a significant predictor of reduced cognitive functioning a decade later.
• Prehypertension category is a relevant and important category that aids early identification of adults not only at risk of developing hypertension and CVD, but also cognitive decline.
